AI-generated analysis. Always verify with the original filing.
Emmaus Life Sciences reported 2025 annual results with net revenues of $12.5 million, down 25% from 2024, but achieved operating income of $0.2 million due to 34% lower operating expenses, alongside a net loss of $7.2 million.
Event Type
Disclosure
Mandatory
Variant
8-K
and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to t
Financial Statements and Exhibits** (d) Exhibits See the accompanying Index to Exhibits, which is incorporated herein by reference. 1 **SIGNATURES** ** ** Pursu
| Metric | Value | Basis |
|---|---|---|
| Revenue, Net | $12.5K | GAAP |
| Gross Profit | $11.6K | GAAP |
| Income (loss) from Operations | $231.00 | GAAP |
| Net Loss | $-7.5K | GAAP |
| Net Loss per Share | $-0.12 | GAAP |